EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Eosinophil Cationic Protein Variation in Patients with Asthma and CRSwNP Treated with Dupilumab

Andrea Giovanni Ledda, Giulia Costanzo iD, Giada Sambugaro iD, Cristiano Caruso iD, Martina Bullita iD, Maria Luisa Di Martino, Paolo Serra, Davide Firinu iD, Stefano Del Giacco

Life · 08.09.2023 · 13 (9) · 1884

DOI: 10.3390/life13091884 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Life, online erschienen am 08.09.2023. Verfasst von Andrea Giovanni Ledda und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Sciences and Public Health, University of Cagliari, 09100 Cagliari, Italy. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Asthma is a clinical syndrome characterized by recurrent episodes of airway obstruction, bronchial hyperresponsiveness and airway inflammation. Most patients with asthma present a “type 2” (TH2) inflammation. ILC2 and TH2 cells release cytokines IL4, IL-13 and IL-5. CRSwNP is a condition characterized by hyposmia or anosmia, nasal congestion, nasal discharge, and face pain or pressure that last for at least 12 weeks in a row without relief. Both asthma and CRSwNP are often characterized by a type 2 inflammation endotype and are often present in the same patient. Dupilumab is a fully human monoclonal antibody targeting the interleukin-4 receptor α (IL-4Rα) subunit, blocking IL4/IL-4Rα binding and IL13. It has been labelled for the treatment of moderate to severe asthma in patients from the age of 12 years with an eosinophilic phenotype, and it has demonstrated efficacy and acceptable safety. Our study aims to investigate the effects of dupilumab on type 2 inflammatory biomarkers, such as eosinophils and eosinophil cationic protein (ECP). ECP is an eosinophil-derived substance contained in granules that are released during inflammation and causes various biological effects, including tissue damage in asthmatic airways.

Methods

ECP, Eosinophil counts (EOS), and total immunoglobulin E (IgE) levels were longitudinally measured using immunoassays in the serum of 21 patients affected by CRSwNP, of which 17 had asthma as a comorbidity, receiving 300 mg dupilumab every two weeks.

Results

The EOS and ECP, after a first phase of significant increase due to the intrinsic characteristic of the block of IL-4 and IL-13, returned to the baseline 10 months after the initial administration of dupilumab. Fractional exhaled nitric oxide (FeNO) and serum total IgE decreased significantly after 9 months. Asthma Control Test (ACT) scores improved after dupilumab treatment. FEV1% and FEV1 absolute registered a significant improvement at 10 months.

Conclusions

Patients who received 300 milligrams of dupilumab every two weeks first experienced a temporary increase in eosinophils (EOS) and eosinophil cationic protein (ECP), then exhibited a gradual decline in these variables with a subsequent return to the initial baseline levels. When compared to the baseline, we observed that the levels of IgE and FeNO decreased over time, while there was an increase in both FEV1 and FEV1%.

Schlagwörter

Stichwörter der Autor:innen

asthmabiomarkersdupilumabeosinophils cationic proteinnasal polypstype 2 inflammation

Autor:innen und Institutionen

  • Department of Medical Sciences and Public Health, University of Cagliari, 09100 Cagliari, Italy.
  • UOSD DH Medicina Interna e Malattie dell'Apparato Digerente, Fondazione Policlinico A. Gemelli IRCCS, 20123 Rome, Italy.
  • Department of Medical Sciences and Public Health, Faculty of Medicine, Università Cattolica del Sacro Cuore, 00168 Rome, Italy.
  • Faculty of Medicine and Surgery, University of Cagliari, 09100 Cagliari, Italy.

ORCID-Profile: Giulia Costanzo, Giada Sambugaro, Cristiano Caruso, Martina Bullita, Davide Firinu

Zitieren

APA

Ledda, A. G., Costanzo, G., Sambugaro, G., Caruso, C., Bullita, M., Di Martino, M. L., Serra, P., Firinu, D., & Del Giacco, S. (2023). Eosinophil Cationic Protein Variation in Patients with Asthma and CRSwNP Treated with Dupilumab. Life, 13(9), 1884. https://doi.org/10.3390/life13091884

Vancouver

Ledda AG, Costanzo G, Sambugaro G, Caruso C, Bullita M, Di Martino ML, et al. Eosinophil Cationic Protein Variation in Patients with Asthma and CRSwNP Treated with Dupilumab. Life. 2023;13(9):1884. doi:10.3390/life13091884

BibTeX
@article{Ledda2023,
  author = {Ledda, Andrea Giovanni and Costanzo, Giulia and Sambugaro, Giada and Caruso, Cristiano and Bullita, Martina and Di Martino, Maria Luisa and Serra, Paolo and Firinu, Davide and Del Giacco, Stefano},
  title = {Eosinophil Cationic Protein Variation in Patients with Asthma and CRSwNP Treated with Dupilumab},
  journal = {Life},
  year = {2023},
  volume = {13},
  number = {9},
  pages = {1884},
  doi = {10.3390/life13091884}
}
Kostenlos starten →